



UNIVERSITY OF COLORADO
HOSPITAL

ANSCHUTZ MEDICAL CAMPUS

**Test Update –
Epstein Barr Virus (EBV) Serology**

Epstein Barr Virus (EBV) panels historically have included the Early Antigen Diffuse (EA-D) antibody as an integral part of the interpretation of current, recent or post EBV infection. The presence or absence of EA-D antibodies is not a critical factor in determining when EBV infection has occurred. Furthermore, the availability of EBV PCR has made anti-EA antibody detection obsolete. We will discontinue the EA-D antibody as a component of our EBV Follow-up Panel (EBVF) as of January 19, 2009.

The EBV Follow-up Panel (EBVF) will include:
EBV Viral Capsid Antigen (VCA) IgM,
EBV VCA IgG and
Epstein Barr Nuclear Antigen (EBNA).

The Epstein Barr Virus Acute Panel (EBVA) will continue to include:
EBV VCA IgM and
EBV VCA IgG.

Please call the Clinical Virology Laboratory at 720-848-7085 if you have any questions or visit our website at <http://clinlab.uch.edu> for additional information.

Issued January 6, 2009

Clinical Laboratory
Medical Director Ronald B. Lepoff, MD